Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer

Clinical trial NCT05306041 · RECRUITING

Trial details

NCT number: NCT05306041
Sponsor: GBG Forschungs GmbH
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

HER2-positive Breast Cancer

Start date: 2023-01-02
Primary completion: 2026-10-01
Enrollment: 170

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.